title: Platelet function testing in practice: a case study.
abstract: Dual antiplatelet therapy with aspirin and a thienopyridine reduces ischemic cardiovascular         events following percutaneous coronary intervention. However, despite this         treatment, residual risk of ischemic events persists. Among other factors, enhanced         platelet reactivity after thienopyridine therapy is associated with an increased risk of         ischemic cardiovascular events. A heterogeneous and variable patient response to the         thienopyridine clopidogrel exists and has been attributed to a number of genetic, pharmacologic,         and clinical factors. Developments in point-of-care platelet function testing         allow for the assessment of on-treatment platelet reactivity after thienopyridine therapy         and thus identify poor responders. We report two cases of stent thrombosis in which         the bedside rapid platelet function VerifyNow P2Y12 Assay® (Accumetrics, San Diego,         CA) was used to determine on-treatment platelet reactivity and identify potential         etiologies of the thrombotic events.
authors.affiliation: University of California, San Diego Medical Center, San Diego, CA, USA.
authors.forename: Ehtisham
authors.initials: E
authors.lastname: Mahmud
authors.forename: Lawrence
authors.initials: L
authors.lastname: Ang
mesh_terms: D000369:Aged, 80 and over; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects*; D001792:Blood Platelets / Q000187:drug effects*; D017023:Coronary Angiography; D016903:Drug Monitoring / Q000379:methods*; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D055118:Medication Adherence; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D010979:Platelet Function Tests; D019095:Point-of-Care Systems; D011237:Predictive Value of Tests; D058925:Receptors, Purinergic P2Y12 / Q000097:blood / Q000187:drug effects; D017131:Thrombectomy; D013927:Thrombosis / Q000097:blood / Q000000981:diagnostic imaging / Q000209:etiology* / Q000628:therapy; D016896:Treatment Outcome
chemical_list: C548576:P2RY12 protein, human; D010975:Platelet Aggregation Inhibitors; D058925:Receptors, Purinergic P2Y12